UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 8, 2018
AIT Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware
|
|
000-55759
|
|
47-3812456
|
|
(State or Other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
2 Ilan Ramon, Science Park
Ness Ziona, 7403635 Israel
|
|
(Address of Principal Executive Office)
|
+972.8.684.3313
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 2, 2018, the Board of Directors (the “Board”) of AIT Therapeutics, Inc. (the “Company”) elected Yoori Lee as a director of the Company. Ms. Lee has replaced Professor Youssef Av-Gay as a director of the Company, who resigned from the Board on January 2, 2018.
Ms. Yoori Lee has served as Co-Founder and President of Trio Health Advisory Group, Inc., a Delaware company, since January, 2013. From February, 1996 to January, 2011, Ms. Lee served as Managing Director and Director of MEDACorp Services at Leerink Partners LLC, a healthcare investment bank. The Company believes Ms. Lee is qualified to serve on the Board because of her extensive consulting experience and her knowledge of the biotechnology industry.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
AIT THERAPEUTICS, INC.
|
|
Date: January 8, 2018
|
By: /s/ Steven Lisi
Name: Steven Lisi
Title: Chief Executive Officer
|